Patient reported outcomes after GON block
| ISRCTN | ISRCTN10430251 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN10430251 |
| Secondary identifying numbers | 38836 |
- Submission date
- 03/09/2018
- Registration date
- 04/09/2018
- Last edited
- 14/04/2022
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Nervous System Diseases
Plain English summary of protocol
Background and study aims
Primary headache disorders, including migraine, cluster headache, and occipital neuralgia, are some of the most debilitating conditions that impact negatively on patients themselves and the wider economy. Some patients do not respond to currently available prophylaxis (preventative) and rescue medication. Nerve block medication treatment is offered to these treatment-resistant patients. Greater occipital nerve (GON) block is an established nerve block procedure that has a favourable safety profile and is cost-effective – the active ingredients used are a mix of local anaesthetic agent and steroid. The exact effectiveness and the best method for delivering GON block is not yet known due to a relative lack of evidence from gold-standard randomised controlled trials and variety in the applied GON block procedure. Initial pilot data on GON block patients, and related evidence from use of anaesthetics in dentistry, suggests that lying a patient down for ten minutes after the procedure enhances the effectiveness of the GON block and thereby leads to an increase in the achieved headache-free period. This present study seeks to determine whether the patient’s position straight after injection of the GON block medicine influences headache symptoms afterwards. A headache-reporting App called Curelator, used by participating patients during the trial, may reduce the bias observed with retrospective patient recall of headache episodes.
Who can participate?
Patients aged 18 or older with primary headache disorder
What does the study involve?
Participants are asked to use the app daily to record any headache(s) experienced, and if so what the characteristics of the headache were (length, intensity, etc). They use the app for a total of 120 days (30 days before GON block, and up 90 days after the GON block). Participants complete up to three questionnaires related to headache disorder and how it impacts on their daily living. At their next appointment for their GON block, they are randomly allocated to one of two patient positions (sitting or lying down) and are asked how painful they thought the GON block procedure was. During the follow-up period the participants are asked to complete the same questionnaires as before at 30 and 90 days after the GON block appointment. In addition they are asked about the relief they have had from the GON block procedure and what they think of the Curelator app. Participants do not have to visit the neurology clinic more often than normal. All follow-up visits can be done remotely, via e-mail, phone or post.
What are the possible benefits and risks of participating?
This study aims to find out if one patient position is more effective than the other in minimising headache-related pain (frequency, intensity etc). At the moment there is some indication that one position is better than the other. However, this has not yet been proven and established, and this study is aimed to assess this. This trial will also assess if the use of a headache-recording app is useful to check a patient’s headache frequency. The Curelator headache app will be provided to participants free of charge and normally retails at about £48. Participants cannot claim payments, reimbursement of expenses or any other benefits or incentives for taking part in this study. There is no personal safety risk anticipated regarding taking part in this study. There is no risk anticipated with sitting up or lying down for 10 minutes after the GON block procedure. Like with any invasive procedure, the GON block procedure itself (which is not classed as a trial intervention) carries risks such as localised bleeding and localised hair loss. If patients decide to take part in the study, and their Neurologist, nurse or the research team learns of important new information that might affect their desire to remain in the study, they will tell the participants as soon as possible. Appropriate precautions are in place to ensure participants’ medical and personal information is kept safe.
Where is the study run from?
1. Cumbria Partnership NHS Foundation Trust (UK)
2. City Hospitals NHS Sunderland Foundation Trust (UK)
3. Hull and East Yorkshire Hospitals NHS Trust (UK)
4. Newcastle upon Tyne Hospitals NHS Foundation Trust (UK)
When is the study starting and how long is it expected to run for?
August 2018 to March 2021
Who is funding the study?
Curelator, Inc.
Who is the main contact?
Dr Leon Jonker
leon.jonker@nihr.ac.uk
Contact information
Scientific
Science & Innovation Manager
Cumbria Partnership NHS Foundation Trust
R&D Department
Carleton Clinic
Carlisle
CA1 3SX
United Kingdom
 ORCID ID |
0000-0001-5867-4663 |
|---|---|
| Phone | +44 (0)1228 602173 |
| leon.jonker@nihr.ac.uk |
Study information
| Study design | Randomised; Interventional; Design type: Treatment, Physical |
|---|---|
| Primary study design | Interventional |
| Secondary study design | Randomised controlled trial |
| Study setting(s) | Hospital |
| Study type | Treatment |
| Participant information sheet | ISRCTN10430251_PIS_v2_23Aug2018.pdf |
| Scientific title | The effect of patient positioning on patient reported outcomes after GON block for primary headache disorder: a multi-centre, four-arm, controlled, prospective randomised trial |
| Study acronym | PARAGON |
| Study objectives | This study seeks to use a prospective, randomised, multi-centre approach to determine whether the patient’s position straight after injection of GON block influences the patient-reported outcomes regarding headache symptoms afterwards. A headache-reporting App called Curelator, used by participating patients during the trial period, will allow prospective recording of headaches which may reduce the bias observed with retrospective patient recall of headache episodes. |
| Ethics approval(s) | South Central - Oxford A Research Ethics Committee, 19/06/2018, ref: 18/SC/0334 |
| Health condition(s) or problem(s) studied | Headache disorder, including migraine, occipital neuralgia, cluster headache and trigeminal autonomic cephalgia |
| Intervention | The patient will first be approached about the study during their clinic visit with the neurologist where it will also be discussed whether the patient is suitable for receiving GON block. If indeed they are listed for GON block a few more checks will be made to see if they are eligible to take part in the PARAGON study. For example, one requirement is that they have access to a smartphone, computer or tablet to use an app to record their headaches. When in the study they are asked to use the app daily to record: any headache(s) experienced, and if so what the characteristics of the headache were (length, intensity, etc). Therefore, they will use the App for a total of 120 days max (30 days before GON block, and up 90 days post-GON block). Once written informed consent has been obtained from the patient, they will be asked about a few baseline items, such as age, sex, height, weight, and some information about their headache disorder diagnosis. They will also be asked to complete up to three questionnaires related to headache disorder and how it impacts on their daily living (HIT-6, MIDAS and MSQ; the latter for migraine patients only). At their next appointment for their GON block, participants will be given single treatment unilateral or bilateral GON block, inserting a 22-23 gauge needle, using dose of Lidocaine 2% (20mg) with Depo-Medrone (80mg) in 2 ml vial, injected close to GON output (1/3 of distance between external protuberance and mastoid process). The intervention is as follows: directly following conclusion of the GON block procedure the patient will either: A. Remain seated vertical (sitting) B. Lie horizontally in a supine position for 10 minutes (with head rested on pillow at approximately 30 degree angle), measured with stopwatch Please note that they will only be randomised if they have completed the Curelator App daily on at least 90% of days in a 30 days period running up to the GON block appointment. During the follow-up period the participants will be asked to complete the same questionnaires as before at 30 and 90 days after the GON block appointment. In addition they will be asked about the relief they have had from the GON block procedure and what they think of the Curelator app. As mentioned, this can be done remotely and they can complete these questionnaires at home. Below is a summary of what happens at each study time point. Study participants do not have to visit the neurology clinic more often than normal. All follow-up visits can be done remotely, via e-mail, phone or post. Baseline (up to 90 days before GON block) visit with Neurologist and researcher in clinic: • Screening for trial eligibility • Written Informed Consent • Info on type of headache, height/weight etc • Questionnaires (HIT6, MIDAS, MSQ) • Complete Curelator App – daily for 30 days GON block procedure visit with Neurologist in clinic: • Randomisation to one of two groups • Patient position after GON block, 10 min. • Pain scale questionnaire after GON block Follow-up visit 1 (30 days after GON block) with Researcher via e-mail/phone/post: • Headache RELIEF questionnaire • Questionnaires (HIT6, MIDAS, MSQ) • Complete Curelator App – daily for 30 days Follow-up visit 2 (90 days after GON block) with Researcher via e-mail/phone/post: • Headache RELIEF questionnaire • Questionnaires (HIT6, MIDAS, MSQ) • Complete Curelator App – daily for another 60 days • Patient experience questionnaire |
| Intervention type | Procedure/Surgery |
| Primary outcome measure | RELIEF (headache relief) patient-reported outcome score at 90 days post-GON block; the score will also be recorded at 30 days post-GON block |
| Secondary outcome measures | 1. Headache-free period post-GON block in days (up to 90 days post-GON block) 2. Average monthly headache days (in 30 days before GON block and up to 90 days post-GON block) 3. Severity of headache (severe, moderate, mild, none; (in 30 days before GON block and 30/90 days post-GON block) 4. Headache characteristics (in 30 days before GON block and 30/90 days post-GON block), including aura, photophobia 5. Average length of each headache episode in hours (in 30 days before GON block and 30/90 days post-GON block) 6. Impact of headache disorder on quality of life (in 30 days before GON block and 30/90 days post-GON block) using HIT-6, modified MIDAS, MSQ validated questionnaires (latter for migraineurs only) 7. Prophylactic and/or rescue medication use: total cost of medicine use (in 30 days before GON block and 30/90 days post-GON block), using British National Formulary as source for costs 8. Adverse event reporting by participants (at 30 days post-GON block) |
| Overall study start date | 30/08/2018 |
| Completion date | 31/03/2021 |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Adult |
| Lower age limit | 18 Years |
| Sex | Both |
| Target number of participants | Planned Sample Size: 84; UK Sample Size: 84 |
| Total final enrolment | 172 |
| Key inclusion criteria | 1. Diagnosis fulfilling IHS criteria for primary headache disorder, which includes: 2. For migraine cohort: 2.1. Episodic or chronic migraine 3. For non-migraine cohort: 3.1. Occipital neuralgia 3.2. Cluster headache 3.3. Trigeminal autonomic cephalgia (TAC) 3.4. Non-specified or other primary headache disorder 4. Deemed eligible for GON block procedure as determined by treating neurology team 5. Aged 18 or older 6. Mental capacity to give written informed consent |
| Key exclusion criteria | 1. Under the age of 18 years 2. Unable to fully understand the consent process and provide informed consent due to either language barriers or mental capacity 3. Any condition that precludes patients from receiving GON block, including: 3.1. Disorders associated with excessive bleeding, coagulation abnormalities or any other significant haematological condition (e.g. Factor V Leiden, haemophilia, thrombocytopaenia). 3.2. Known acute or previous base of skull fracture 3.3. Allergy or hypersensitivity to any active ingredients or excipients used for GON block 4. Patients who are participating in another interventional research study involving an investigational product related to their headache disorder 5. The patient has concurrent (medical) conditions that in the opinion of the investigator may compromise patient safety or study objectives 6. Subjects who have received greater occipital nerve blocks (both GON or Botox) in the last 6 months, or are still headache-free following an intervention 7. For randomisation after baseline period: 7.1. Less than two headache episodes in baseline 30 day data collection period 7.2. Curelator App used < 90% of 30 day baseline diary period |
| Date of first enrolment | 10/09/2018 |
| Date of final enrolment | 31/12/2020 |
Locations
Countries of recruitment
- England
- United Kingdom
Study participating centres
Penrith
CA11 8JA
United Kingdom
Sunderland
SR4 7TP
United Kingdom
Anlaby Rd
Hull
HU3 2JZ
United Kingdom
Newcastle
NE1 4LP
United Kingdom
Sponsor information
Hospital/treatment centre
c/o Mrs Barbara Cooper
R&D Manager
Carlisle
CA1 3SX
England
United Kingdom
| Phone | +44 (0)1228 608926 |
|---|---|
| Barbara.cooper@cumbria.nhs.uk |
Funders
Funder type
Industry
No information available
Results and Publications
| Intention to publish date | 30/09/2022 |
|---|---|
| Individual participant data (IPD) Intention to share | Yes |
| IPD sharing plan summary | Other |
| Publication and dissemination plan | Planned publication in a high-impact peer reviewed journal. |
| IPD sharing plan | The datasets generated and/or analysed during the current study during this study will be included in the subsequent results publication. |
Study outputs
| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| Participant information sheet | version v2 | 23/08/2018 | 04/09/2018 | No | Yes |
| Protocol file | version v2 | 23/08/2018 | 04/09/2018 | No | No |
| Protocol file | version v4 | 26/02/2019 | 12/07/2019 | No | No |
| Protocol file | version V6 | 04/02/2020 | 21/09/2020 | No | No |
| Plain English results | 14/04/2022 | 14/04/2022 | No | Yes | |
| HRA research summary | 28/06/2023 | No | No |
Additional files
- ISRCTN10430251_PIS_v2_23Aug2018.pdf
- Uploaded 04/09/2018
- ISRCTN10430251_PROTOCOL_v2_23Aug2018.pdf
- Uploaded 04/09/2018
- ISRCTN10430251_PROTOCOL_v4_26Feb2019.docx
- Uploaded 12/07/2019
- ISRCTN10430251_PROTOCOL_V6_04Feb20.docx
- Uploaded 21/09/2020
- ISRCTN10430251_ResultsPlainEnglish_14Apr2022.pdf
Editorial Notes
14/04/2022: The following changes have been made:
1. A plain English results file has been uploaded.
2. The intention to publish date has been changed from 30/06/2020 to 30/09/2022.
22/09/2020: The following changes were made to the trial record:
1. The overall trial end date was changed from 30/11/2019 to 31/03/2021.
2. The intention to publish was changed from 01/03/2020 to 30/06/2020.
3. The total final enrolment number was added.
21/09/2020: The recruitment end date was changed from 30/09/2019 to 31/12/2020. Uploaded protocol Version 6, 4 February 2020 (not peer reviewed).
12/07/2019: The recruitment end date was changed from 30/06/2019 to 30/09/2019. Uploaded protocol Version 4, 26 February 2019 (not peer reviewed).
28/03/2019: The condition has been changed from "Specialty: Neurological Disorders, Primary sub-specialty: Other; Health Category: Neurological; Disease/Condition: Episodic and paroxysmal disorders" to "Headache disorder, including migraine, occipital neuralgia, cluster headache and trigeminal autonomic cephalgia" following a request from the NIHR.
05/10/2018: Internal review.
04/09/2018: Uploaded protocol Version 2, 23 August 2018 (not peer reviewed).
